Theriva Biologics, Inc.(TOVX)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Theriva Biologics, Inc. (TOVX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TOVX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $2.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of TOVX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, JANE STREET GROUP, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. TOVX trades on the NYSE exchange and files with the SEC under CIK 894158. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TOVX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theriva Biologics, Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-3.2M

TOVX key financials by period

Theriva Biologics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 201010-K/A$2.6M$-1.7M-41.4%

Institutions holding TOVX

Institutional investors reporting a position in Theriva Biologics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
VANGUARD CAPITAL MANAGEMENT486,179$121.5K2026-06-30
JANE STREET GROUP331,922$83.0K2026-06-30
GEODE CAPITAL MANAGEMENT294,021$73.6K2026-06-30
VANGUARD FIDUCIARY241,780$60.4K2026-06-30
Ikarian Capital112,076$28.0K2026-06-30
Virtu Financial87,138$22.0K2026-06-30
NORTHERN82,700$20.7K2026-06-30
RENAISSANCE TECHNOLOGIES63,710$15.9K2026-06-30
UBS Group AG61,053$15.3K2026-06-30
XTX Topco Ltd53,868$13.5K2026-06-30
SEC EDGAR: CIK 894158 →
TOVX

Theriva Biologics, Inc.

TOVX
NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $2.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$0

Net Income

Q2 2026
EDGAR

$-3.22M

EPS (Diluted)

Q2 2026
EDGAR

$-0.07

Top Institutional Holders

as of Q2 2026
$495.5K total
VANGUARD CAPITAL MANAGEMENT LLC
$121.5K+152.7%
JANE STREET GROUP, LLC
$83.0K+87.5%
GEODE CAPITAL MANAGEMENT, LLC
$73.6K-34.7%
VANGUARD FIDUCIARY TRUST CO
$60.4K0.0%
Ikarian Capital, LLC
$28.0K0.0%
Virtu Financial LLC
$22.0K-65.6%
NORTHERN TRUST CORP
$20.7KNew
RENAISSANCE TECHNOLOGIES LLC
$15.9KNew
UBS Group AG
$15.3K-72.9%
XTX Topco Ltd
$13.5K-43.1%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…